US FDA approves GSK's second lung cancer drug from historic Nuvalent deal
GSK•The FDA granted accelerated approval to GSK's neladalkib for advanced non-small cell lung cancer that has progressed after ALK inhibitor treatment. The drug, acquired through GSK's $10.6 billion Nuvalent deal, is the second lung cancer therapy from the deal to win FDA approval.
1. FDA approval
The FDA granted accelerated approval to GSK's once-daily oral therapy neladalkib, sold as Nelkarmi, for patients with advanced non-small cell lung cancer whose disease progressed after treatment with ALK tyrosine kinase inhibitors. The approval offers a new treatment option for patients who have exhausted existing targeted therapies, for whom chemotherapy has often been the main remaining choice.
2. Nuvalent deal
GSK acquired neladalkib and another late-stage lung cancer drug, Jideytro, in its $10.6 billion acquisition of Nuvalent, completed in July. Jideytro won FDA approval the same month.
3. Trial and competition
The application was based on a trial in which neladalkib shrank tumors, including tumors that had spread to the brain, in patients previously treated with ALK-targeted drugs. It will compete with Roche's Alecensa and Pfizer's Lorbrena, and is being studied against Alecensa in a late-stage trial as a potential first-line treatment.




